Aplagon

Founded on pioneering research by Riitta Lassila and associates at the Wihuri Research Institute in Helsinki, Aplagon is a clinical-stage biopharmaceutical company dedicated to developing first-in-class therapeutics for thromboinflammatory diseases, addressing critical unmet medical needs in vascular medicine. Its lead therapeutic, APAC, a heparin proteoglycan mimetic, is a dual AntiPlatelet and AntiCoagulant (APAC) with unique antithrombotic and anti-inflammatory properties. Designed to specifically target vascular injury sites, APAC provides localized, long-term action while minimizing systemic exposure. The company’s clinical pipeline focuses on addressing thromboinflammatory conditions, with lead indications in arteriovenous fistula (AVF) maturation failure for hemodialysis patients and chronic limb threatening ischemia (CLTI) to prevent amputations and major cardiovascular events.